
|Articles|March 31, 2022
The Science Behind Using Circulating Tumor DNA for MCC
Author(s)Mary Scoviak, Managing Editor
In this second part of a 4 part video series, Lisa Zaba, MD, PhD, FAAD, explains the data behind the clinical trials on using circulating tumor DNA for merkel cell carcinoma (MCC). She expands on her talk from the 2022 American Academy of Dermatology Annual Meeting.
Advertisement
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Dermatology Times
1
Switching from Biologics to Upadacitinib Yields Progressive Improvements in Moderate to Severe AD
2
Systemic JAK Inhibitors for Vitiligo: Emerging Clinical Trial Data and Safety Considerations
3
Real-World Study Finds Experienced Dermatologists Outperform AI in Skin Cancer Diagnosis
4
How Dermatologists Can Incorporate GLP-1 Receptor Agonists Into Psoriasis Care
5












